Avantor recorded slightly lower sales in its fourth quarter due to unfavorable foreign exchange rates, though its earnings were boosted by a divestiture. The biopharma supplier posted a profit of $500 ...
Q4 2024 Management View Michael Stubblefield, CEO, highlighted Avantor's return to growth in Q4 2024 with low single-digit organic growth and strong bioprocessing performance, achieving high ...
Some results have been hidden because they may be inaccessible to you